CD40 Ligand Blockade for Prevention of Graft-Versus-Host Disease This scoping review was conducted based on the Arksey and O'Malley framework and the work of Levac et al. The databases searched ...

This study evaluated three LLMs (GPT-3.5-turbo-0125, GPT-4-turbo, and GPT-4o) using drug names from HemOnc ontology. The assessment included 367 generic-to-brand and 2,516 brand-to-generic pairs, ...

In the article that accompanies this editorial, Babiker et al 12 present the data that tumor-treating fields (TTFs) combined with gemcitabine plus nab-paclitaxel improved median overall survival ...

Long-Term Follow-Up of E3311, an ECOG-ACRIN Cancer Research Group Phase II Trial of Transoral Surgery and Risk-Based Adjuvant Treatment in Human Papillomavirus–Initiated Oropharynx Cancer Despite ...

Authorship Contributions. JCO Journals adhere to the guidelines on authorship established by the International Committee of Medical Journal Editors (ICMJE) statement on the role of Authors and ...

Background: Despite recent FDA approval of immune checkpoint inhibitor (ICI) and antibody-drug conjugates (ADCs), therapeutic options for metastatic triple negative breast cancer (mTNBC) remain ...

Phase II Study (NO LIMIT, WJOG13320G) of First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability–High Advanced Gastric or Esophagogastric Junction Cancer ...

Treatment Patterns of Goserelin 3.6 mg Once Every 4 Weeks and 10.8 mg Once Every 12 Weeks in Women With Breast Cancer: A Real-World Analysis of Patients in the United States This is a retrospective, ...

View the current volume of the ASCO Educational Book ...

The art of sequencing therapy in the management of breast cancer is a multifaceted challenge that demands the careful integration of clinical trial data, real-world evidence, and individualized ...

Guidelines on female and male breast cancer treatment, including use of adjuvant systemic therapies, biomarker test use, and the role of targeted treatments for subtypes like hormone receptor-positive ...

On August 6, 2024, the US Food and Drug Administration (FDA) approved 2 vorasidenib based on results of the INvestigating VorasiDenib In Glioma (INDIGO) trial 3 for patients age ≥12 years with grade 2 ...